Role of chemokines and chemokine receptors in prostate cancer development and progression

Journal of Cancer Science and Therapy

Volumn 2, Issue 4, 2010, Pages 89-94

  Singh, Rajendra K ^a,b   Sudhakar, Akulapalli ^c,d,e   Lokeshwar, Bal L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Veterans Administration Miami Hospital   (United States)

^c BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; INTERLEUKIN 8;

CANCER GROWTH; CANCER RISK; GENETIC POLYMORPHISM; HUMAN; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 77954983359     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000030     Document Type: Review

References (80)

1. Alibhai SM, Leach M, Tomlinson G, Krahn MD, Fleshner N, et al. (2005) 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 97: 1525-1532.
2. Aragon-Ching JB, Madan RA, Dahut WL (2010) Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol 2010: 361836.
3. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, et al. (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862.
4. Aus G, Ahlgren G, Bergdahl S, Hugosson J (1996) Infection after transrectal core biopsies of the prostate risk factors and antibiotic prophylaxis. Br J Urol 77: 851-855.
5. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, et al. (2002) The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62: 1093-1102.
6. Ben-Baruch A (2008) Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25: 345-356.
7. Bingle L, Lewis CE, Corke KP, Reed MW, Brown NJ (2006) Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br J Cancer 94: 101-107.
8. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490.
9. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7: 122-133.
10. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, et al. (1999) Point mutation causing constitutive signaling of CXCR2 leads to transforming activitysimilar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol 163: 2017-2022.
11. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213.
12. Charbonnier AS, Kohrgruber N, Kriehuber E, Stingl G, Rot A, et al. (1999) Macrophage inflammatory protein 3αis involved in the constitutive trafficking of epidermal langerhans cells. J Exp Med 190: 1755-1768.
13. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, et al. (2010) Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One 5: e8736.
14. Christopherson K 2nd, Hromas R (2001) Chemokine regulation of normal and pathologic immune responses. Stem Cells 19: 388-396.
15. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
16. Civenni G, Sommer L (2009) Chemokines in neuroectodermal development and theirpotential implication in cancer stem cell-driven metastasis. Semin Cancer Biol 19: 68-75
17. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, et al. (2008) Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9: 445-452.
18. Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286: 2098-2102.
19. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, et al. (2009) The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4: e6695.
20. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269.
21. Denberg TD, Melhado TV, Steiner JF (2006) Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote. Cancer 107: 620-630.
22. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ (2002) The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 95: 287-295.
23. Gerard C, Rollins BJ (2001) Chemokines and disease. Nat Immunol 2: 108-115.
24. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 121: 1571-1578.
25. Gladson CL, Welch DR (2008) New insights into the role of CXCR4 in prostate cancermetastasis. Cancer Biol Ther 7: 1849-1851.
26. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, et al. (2001) Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19: 2517-2526.
27. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-1262.
28. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44: 1667-1673.
29. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D (2006) S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312: 184-197.
30. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, et al. (2007) CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 13: 5056-5062.
31. Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2: 175-184.
32. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, et al. (2000) Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 164: 3465-3470.
33. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388-1413.
34. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
35. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, et al. (2004) NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 64: 5489-5495.
36. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, et al. (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50: 203-15.
37. Kim CH (2004) Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 4: 343-361.
38. Koukourakis G, Kelekis N, Armonis V, Kouloulias V (2009) Brachytherapy for prostatecancer: a systematic review. Adv Urol 2009: 327945.
39. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC (2005) Upregulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 65: 9891-9898.
40. Lim AJ, Brandon AH, Fiedler J, Brickman AL, Boyer CI, et al. (1995) Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 154: 1420-1425.
41. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5: 21-28.
42. Mazur DJ, Merz JF (1996) How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. J Am Geriatr Soc 44: 934-937.
43. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, et al. (1999) Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 154: 1503-1512.
44. Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36: 71-78.
45. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127.
46. Nacusi LP, Tindall DJ (2009) Androgen receptor abnormalities in castrationrecurrentprostate cancer. Expert Rev Endocrinol Metab 4: 417-422.
47. Nelson WG, De Marzo AM, DeWeese TL (2001) The molecular pathogenesis of prostatecancer: Implications for prostate cancer prevention. Urology 57: 39-45.
48. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S (2002) Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gammainducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in thesalivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 46: 2730-2741.
49. Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947-970.
50. Pienta KJ, Loberg R (2005) The "emigration, migration, and immigration"of prostate cancer. Clin Prostate Cancer 4: 24-30.
51. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, et al. (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96: 1358-1367.
52. Rietbergen JB, Kruger AE, Kranse R, Schröder FH (1997) Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 49: 875-880.
53. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, et al. (2009) Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 69: 1774-80.
54. Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242.
55. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M (2007) Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109: 2392-2404.
56. Sadeghi-Nejad H, Wasserman M, Weidner W, Richardson D, Goldmeier D (2010) Sexually transmitted diseases and sexual function. J Sex Med 7: 389-413.
57. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187: 875-883.
58. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328.
59. Schweickart VL, Epp A, Raport CJ, Gray PW (2000) CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines. J Biol Chem 275: 9550-9556
60. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, et al. (2007) Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52: 964-72.
61. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 121: 1424-1432.
62. Singh RK, Lokeshwar BL (2009) Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs. Mol Cancer 8: 57.
63. Singh S, Sadanandam A, Singh RK (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26: 453-67.
64. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
65. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, et al. (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96: 317-322.
66. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99: 1516-1524.
67. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, et al. (2005) Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64: 40-49.
68. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, et al. (2008) Inflammation and prostate cancer. Future Oncol 4: 637-645.
69. Vicari AP, Caux C (2002) Chemokines in cancer. Cytokine Growth Factor Rev 13: 143-154.
70. Vindrieux D, Escobar P, Lazennec G (2009) Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16: 663-673.
71. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, et al. (2007) The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 100: 733-737.
72. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, et al. (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: 927-936.
73. Waugh DJ, Wilson C, Seaton A, Maxwell PJ (2008) Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4595-4604.
74. Xie H, Huang HC, Yang YR, He QX, Zhu QJ, et al. (2010) Expressions of bacterial 16S rRNA, IL-1beta, TNF-alpha and NGF in prostate tissues. Zhonghua Nan Ke Xue 16: 40-43.
75. Yanamandra K, Alexeyev O, Zamotin V, Srivastava V, Shchukarev A, et al. (2009) Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS One 4: e5562.
76. Yao SL, Lu-Yao G (1999) Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 91: 1950-1956.
77. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, et al. (1998) Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 273: 16551-16554
78. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162: 5671-5675.
79. Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14: 181-185.
80. Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role inimmunity. Immunity 12: 121-127.